Background: Pyrvinium pamoate (PP) is an old drug approved by the FDA for the treatment of pinworm
infections. Recently, it has been introduced as an anti-tumor agent, however, low aqueous solubility
severely limits its potential effects. In this study, we developed a liposomal formulation of pyrvinium pamoate
to investigate its in vitro cytotoxicity and in vivo efficacy against melanoma cells.
Materials & Methods: As drug carriers, liposomes were fabricated using the thin-film method. PP was encapsulated
within the liposomes using a remote loading method. We evaluated the morphology, particle size, and Zeta
potential of the liposomes. Additionally, high-performance liquid chromatography (HPLC) was employed
for qualitative and quantitative analysis. Then we investigated our liposomal PP for its in vitro cytotoxicity as
well as the tumor growth inhibition in C57BL/6 mice bearing B16F0 melanoma tumors.
Results: Based on the analytical result, the liposomal drug delivery system is a homogeneous and stable colloidal
suspension of PP particles. The images of Atomic force microscopy and particle size data showed that all
the prepared nanocarriers were spherical with a diameter of approximately 101 nm. According to both in vitro
and in vivo studies, nanoliposomal PP exhibited an improved anti-proliferative potential against B16F10 melanoma
tumor compared to free PP.
Conclusion: Liposomal encapsulation improves the water solubility of PP and enhances its anti-cancer activity.